Medarex (883040) mit guter News. Heute Tagesgewinner an der Nasdaq? - 500 Beiträge pro Seite

[J.Nebler]

Im Instinet schon bei $4,68 und die meisten Amis schlafen noch!

Medarex Announces Fully Human Antibody MDX-060 Demonstrates Anti-Tumor Activity in Animal Models

Monday December 9, 6:01 am ET
Pre-clinical Data Presented at the American Society of Hematology Annual Meeting


PRINCETON, N.J., Dec. 9 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX - News) announced today that treatment with its fully human antibody, MDX-060, resulted in substantial tumor regression in SCID mice xenografted with CD30-positive lymphomas, with complete disappearance of established subcutaneous tumors in two of five mice. In a second study, three of five mice showed no signs of disease after treatment in a disseminated tumor animal model. These studies were conducted in collaboration with Peter Borchmann, M.D., at the University of Cologne in Germany. The results were presented at the annual meeting of the American Society of Hematology held in Philadelphia from December 6-10, 2002. (Abstract #2258)
ADVERTISEMENT


Medarex is currently conducting a multi-center, dose-escalation Phase I/II clinical study to evaluate MDX-060 in up to 40 patients with refractory or relapsed Hodgkin`s lymphoma, anaplastic large cell lymphoma (ALCL) and other CD30-positive lymphomas. Patients are receiving the MDX-060 antibody weekly for four weeks and will be followed to assess disease response.

In an earlier dose-escalation Phase I clinical study involving an anti- CD30 bispecific antibody generated by Medarex, refractory Hodgkin`s lymphoma patients were evaluated for tumor response and toxicity. Of the 10 patients treated, one patient achieved a complete response lasting three months, and three patients achieved partial responses lasting up to five months. The data indicated that the product was generally well tolerated. This Phase I study of a first generation anti-CD30 bispecific antibody was published in the November 1 issue of Blood (Vol. 100: 3101-3107, 2002).

"We believe that CD30 is a promising target for immunotherapy and are excited to see signs of anti-tumor activity in this pre-clinical study," said Donald L. Drakeman, President and CEO of Medarex. "We look forward to seeing the results of the on-going clinical trial."

About MDX-060

MDX-060 is a fully human antibody that targets CD30, a member of the tumor necrosis factor receptor superfamily and a molecule found on activated lymphocytes. CD30 has been found to be over-expressed in several lymphoproliferative disorders and is present on malignant cells of Hodgkin`s lymphoma and ALCL, as well as other lymphomas and cancers. According to the American Cancer Society, there are nearly 100,000 cases of Hodgkin`s lymphoma and ALCL worldwide.

For further information regarding MDX-060 and clinical trial information, please send an e-mail to [e-mail].

Medarex is a biopharmaceutical company focused on the discovery and development of therapeutics to treat life-threatening and debilitating diseases. Medarex`s UltiMAb Human Antibody Development System(SM) is a unique combination of human antibody technologies that Medarex believes enables the rapid creation and development of fully human antibodies for a wide range of potential disease targets for therapeutic antibody products, including products for the treatment of cancer, inflammation, autoimmune and infectious diseases. Medarex`s product pipeline is based on a variety of therapeutic antibody products developed through the use of its UltiMAb technology. Medarex creates and develops fully human antibodies for itself and others, offering a full range of antibody related capabilities, including pre-clinical and clinical development supported by cGMP manufacturing services. For more information about Medarex, visit its Web site at http://www.medarex.com.

Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believes"; "anticipates"; "intends"; "plans"; "expects"; "estimates"; "could"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product discovery and development as well as risks detailed from time to time in Medarex`s public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2001 and subsequent Quarterly Reports on Form 10-Q. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex`s public disclosure filings are available from its investor relations department.

Medarex®, the Medarex logo, UltiMAb(TM) and UltiMAb Human Antibody Development System(SM) are trademarks and service marks of Medarex, Inc. All rights are reserved.

[J.Nebler]

4,65 Euro Geld in Deutschland.
Glückwunsch an die, die mit 4,5 Euro noch was bekommen haben.
Nicht unter 5 rausgehen!

Gruß

[lux2001]

Meine gebe ich nicht her.
Unter 15 $ auf gar keinen Fall.
Ich weiss ich bin bescheuert

Salut